Durability of protection from original monovalent and bivalent COVID-19 vaccines against COVID-19-associated hospitalization and severe in-hospital outcomes among adults in the United States — September 2022–August 2023

Competing Interest Statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Samuel Brown reports that ReddyPort pays royalties for a patent, outside the submitted work. Steven Chang reports consulting fees from PureTech Health and Kiniksa Pharmaceuticals, outside the submitted work. Abhijit Duggal reports participating on an advisory board for ALung Technologies, outside the submitted work. Manjusha Gaglani reports grants from CDC, CDC-Abt Associates, CDC-Westat, and served as co-chair of the Infectious Diseases and Immunization Committee for the Texas Pediatric Society (TPS) and received an honorarium serving as a TPS Project Firstline webinar speaker panelist for "Respiratory Virus Review: Clinical Considerations and IPC Guidance", outside the submitted work. Michelle N. Gong reports a grant from NHLBI and CDC, fees for serving on Scientific Advisory Panel for Philips Healthcare, travel to ATS conference as board member, outside the submitted work. Carlos Grijalva reports grants from NIH, CDC, AHRQ, FDA, and Syneos Health; receipt of compensation for participation in an advisory board for Merck, outside the submitted work. Natasha Halasa reports receiving grants from Sanofi, Merck, and Quidel, outside the submitted work. Adam Lauring reports receiving grants from CDC, FluLab, NIH/National Institute of Allergy and Infectious Diseases, and Burroughs Wellcome Fund, and MDHHS, and consulting fees from Roche related to baloxavir, outside the submitted work. Christopher Mallow reports Medical Legal Consulting, outside the submitted work. Ithan D. Peltan reports grants from NIH, and Janssen Pharmaceuticals and institutional support Regeneron, outside the submitted work. Mayur Ramesh reports participating in a non-branded Speaker Program supported by AstraZeneca and MD Briefcase, and participating on an advisory board for Moderna, Pfizer, and Ferring, outside the submitted work. No other potential conflicts of interest were disclosed.

Funding Statement

Primary funding for this work was provided by the United States Centers Disease Control and Prevention (contract 75D30122C14944 to Dr. Wesley Self). Scientists from the funding source, the United States Centers for Disease Control and Prevention, participated in all aspects of this study, including its design, analysis, interpretation of data, writing the report, and the decision to submit the article for publication. Scientists from the United States Centers for Disease Control and Prevention are included as authors on this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

These activities were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site, and were conducted in accordance with applicable federal law and CDC policy (45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes